Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice

Biochemical and Biophysical Research Communications
Sehyoun YoonJa-Hyun Baik

Abstract

Many atypical antipsychotic drugs cause weight gain, but the mechanism of this weight gain is unclear. To dissect the role of the dopamine D2 receptor (D2R), an important receptor in the pharmacology of antipsychotic drugs, we analyzed the effect of olanzapine, risperidone, and ziprasidone on changes in body weight and food intake in male wild-type (WT) and D2R knockout (D2R(-/-)) mice. The oral delivery of atypical antipsychotics, olanzapine (5 and 10mg/kg), risperidone (0.1 and 1.0mg/kg) and ziprasidone (10 and 20mg/kg) in both strains mice for 2 weeks suppressed body weight gain, except for olanzapine treatment in D2R(-/-) mice. Olanzapine treatment suppressed body weight gain and decreased food intake in WT mice, but also reduced fat body mass and locomotor activity, whereas D2R(-/-) mice did not show these changes. Ziprasidone and risperidone treatment produced similar responses in WT and D2R(-/-) mice. These data suggest the involvement of D2R in the effect of olanzapine on metabolic regulation. Further studies are required to explore the implications of D2R activity in antipsychotic-mediated metabolic complications.

References

May 1, 1993·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández
Jan 1, 1997·Critical Reviews in Neurobiology·R PicettiE Borrelli
Feb 24, 2001·Lancet·G J WangJ S Fowler
Dec 31, 2002·Journal of Psychopharmacology·Andrew J GoudieJason C G Halford
May 22, 2003·Pharmacology, Biochemistry, and Behavior·B PouzetS Velschow
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Apr 3, 2004·Nature Reviews. Drug Discovery·Bryan L RothWesley K Kroeze
Apr 15, 2004·Molecular and Cellular Neurosciences·Juan Ji AnJa-Hyun Baik
May 12, 2004·Behavioural Brain Research·Anibal A ArjonaRichard J Wurtman
Sep 1, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M J FellK M Marshall
Dec 31, 2004·The American Journal of Psychiatry·Karen A GrahamJoyce B Harp
Mar 30, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M B CopeD B Allison
Jul 30, 2005·Diabetes, Obesity & Metabolism·A J GoudieJ C G Halford
Apr 28, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sung Yul KimJa-Hyun Baik
Jun 21, 2006·Journal of Psychopharmacology·Gavin P ReynoldsShona L Kirk
Apr 10, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Luca PaniGiorgio Marchese
Sep 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Bernard MasriMarc G Caron
Feb 17, 2009·European Journal of Pharmacology·Yoshihiro TadoriTetsuro Kikuchi
Mar 27, 2009·Schizophrenia Research·Bruce ParsonsCynthia Siu
Jan 19, 2010·The Journal of Biological Chemistry·Kyu Seok KimJa-Hyun Baik

❮ Previous
Next ❯

Citations

Aug 18, 2010·The Pharmacogenomics Journal·D J MüllerJ L Kennedy
Nov 20, 2012·Journal of Nutrition in Gerontology and Geriatrics·Roschelle Heuberger
Jun 22, 2012·Journal of the Academy of Nutrition and Dietetics·Joseph I Boullata, Lauren M Hudson
Jan 7, 2021·International Journal of Molecular Sciences·Hsiao-Pei TsaiGeng-Ruei Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here